FDA Approves HEPZATO KIT for Adults Metastatic With Uveal Melanoma
Source: Targeted Oncology, August 2023
The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.
- Approval of Hepzato KIT marks the first approval of a liver-directed therapy for patients with metastatic uveal melanoma.
- The Hepzato KIT is designed to aid doctors in conducting percutaneous hepatic perfusion.
- Hepzato KIT includes an FDA box warning of possible toxicity related to the procedure.
The FDA has granted approval to the HEPZATO KIT (melphalan/Hepatic Delivery System [HDS]). This is a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
READ THE ORIGINAL FULL ARTICLE